ClinicalTrials.Veeva
Menu

Find clinical trials for Lung Cancer in Birmingham, AL

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Cancer
Small Cell Lung Carcinoma
Colorectal Cancer
Squamous Cell Carcinoma of Head and Neck
Breast Cancer
Carcinoma

Lung Cancer trials near Birmingham, AL, USA:

Study With Various Immunotherapy Treatments in Participants With Lung Cancer (EDGE-Lung)

The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tole...

Active, not recruiting
Advanced Non-Small Cell Lung Cancer
Drug: Docetaxel
Drug: Zimberelimab

Phase 2

Gilead Sciences
Gilead Sciences

Birmingham, Alabama, United States and 50 other locations

Locations recently updated

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participants with extensive stage-small cell lung...

Enrolling
Extensive Stage-small Cell Lung Cancer
Drug: Carboplatin
Drug: Ifinatamab deruxtecan

Phase 1, Phase 2

Daiichi Sankyo
Daiichi Sankyo

Birmingham, Alabama, United States and 58 other locations

An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer

This study is being done to determine the efficacy and safety of cofetuzumab pelidotin in the PTK7-expressing, recurrent non-small cell lung ...

Active, not recruiting
Non-small Cell Lung Cancer (NSCLC)
Cancer
Drug: Cofetuzumab Pelidotin

Phase 1

AbbVie
AbbVie

Birmingham, Alabama, United States and 25 other locations

A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) (DeLLphi-301)

The main aim of this study is to:* evaluate safety and efficacy (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST 1.1\]...

Active, not recruiting
Relapsed/Refractory Small Cell Lung Cancer
Drug: Tarlatamab

Phase 2

Amgen
Amgen

Birmingham, Alabama, United States and 80 other locations

A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer

survival compared with carboplatin, etoposide, and nivolumab alone in newly diagnosed participants with extensive-stage small cell lung cancer...

Active, not recruiting
Extensive-stage Small Cell Lung Cancer
Drug: Etoposide
Drug: Carboplatin

Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Birmingham, Alabama, United States and 38 other locations

Phase 2 Safety and Efficacy Evaluation of AL8326 in ≥2nd Line SCLC

efficacy of using oral AL8326 , a multi-targeted receptor Tyrosine Kinase Inhibitor( TKI) , to recurrent, advanced, or metastatic small cell lung...

Active, not recruiting
Small Cell Lung Cancer
Drug: AL8326 low dose group
Drug: AL8326 middle dose group

Phase 2

Advenchen

Birmingham, Alabama, United States and 5 other locations

Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

and antitumor activity of silevertinib (BDTX-1535). The study population comprises adults with either advanced/metastatic non-small cell lung...

Active, not recruiting
Advanced Non-Small Cell Squamous Lung Cancer
Advanced Lung Carcinoma
Drug: silevertinib (BDTX-1535) monotherapy

Phase 1, Phase 2

Black Diamond Therapeutics

Birmingham, Alabama, United States and 28 other locations

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equa...

Enrolling
Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Cancer Metastatic
Drug: Docetaxel monotherapy
Drug: PF-08046054

Phase 3

Pfizer
Pfizer

Birmingham, Alabama, United States and 85 other locations

Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)

followed by durvalumab ± tremelimumab maintenance therapy versus EP alone as first-line treatment in patients with extensive-stage small-cell lung...

Active, not recruiting
Small Cell Lung Carcinoma Extensive Disease
Drug: Carboplatin
Drug: Tremelimumab

Phase 3

AstraZeneca
AstraZeneca

Birmingham, Alabama, United States and 206 other locations

A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer

This study will evaluate REGN5093 for the treatment of Non-Small Cell Lung Cancer (NSCLC) with MET alteration. The main purpose of ...

Enrolling
NSCLC
Drug: REGN5093

Phase 1, Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Birmingham, Alabama, United States and 32 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems